ملخص
Deferiprone is an oral chelating agent that has been recently shown to reduce cardiac siderosis, but is also known to be associated with serious side effects like agranulocytosis which can be fatal. This report is a single centre experience of 5 cases with severe agranulocytosis in amongst 144 patients (3.47%) of thalassemia major on combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone which is much higher than the previous reports.
اللغة الأصلية | English |
---|---|
الصفحات (من إلى) | 275-277 |
عدد الصفحات | 3 |
دورية | Oman Medical Journal |
مستوى الصوت | 23 |
رقم الإصدار | 4 |
حالة النشر | Published - أكتوبر 2008 |
ASJC Scopus subject areas
- ???subjectarea.asjc.2700.2700???